- Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order
- Anesthesiologists’ Group Urges Limits on Ketamine Use
- ‘E-reporting’ Daily Symptoms Boosts Cancer Patients’ Well-Being
- Weight-Obsessed Teens Face Triple the Odds for Self-Harm
- Wrong Smartphone Settings Can Lead to Missed Alerts From Linked Diabetes Devices
- CDC: U.S. Influenza Activity in the United States Remains Elevated
- Federal Judge Halts NIH Cuts That Could Impact Medical Research
- GLP-1 Meds Can Work Wonders for Kidney Health
- Shark Attacks Plummeted Worldwide Last Year
- Most Americans Keep Chronic Health Conditions Hidden at Work: Poll
Opdivo Approved for Advanced Melanoma

Opdivo (nivolumab) has been approved by the U.S. Food and Drug Administration to treat advanced melanoma skin cancer that has either spread or can’t be treated with surgery, the agency said Monday.
Melanoma, the fifth most common skin cancer in the United States, will strike more than 76,000 Americans this year and more than 9,700 will die from it, the U.S. National Cancer Institute projects.
Opdivo inhibits a protein that prevents the body’s immune system from attacking melanoma tumors, the FDA said in a news release.
The drug’s safety and effectiveness were evaluated in clinical studies involving 120 people with melanoma that had either spread or couldn’t be removed by surgery. Some 32 percent of people who took the drug had their tumors shrink, and this effect lasted for more than six months in about one-third of these people, the FDA said.
Common side effects included rash, itching, cough, respiratory infection and fluid retention. More serious adverse reactions included immune system impairment involving the lung, colon, liver or kidneys, the FDA said.
Opdivo is marketed by Bristol-Myers Squibb, based in Princeton, N.J.
More information
To learn more about this approval, visit the FDA.
Source: HealthDay
Copyright © 2025 HealthDay. All rights reserved.